Usefulness of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in clinical characterisation of children with newly diagnosed Crohn's disease.
Crohn's disease
children
metalloproteinase-9
tissue inhibitor of metalloproteinase-1
Journal
Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
19
12
2019
revised:
23
03
2020
accepted:
06
04
2020
pubmed:
5
5
2020
medline:
15
5
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
The aim of this study was to determine the relation of non-invasive markers representing gut mucosal damage (metalloproteinase-9 (MMP-9)) and remodelling (tissue inhibitor of metalloproteinase-1 (TIMP-1)) with Crohn's disease (CD) phenotype, disease activity scores (clinical and endoscopic) and radiological evaluation of the ileum in newly diagnosed children. Serum and faecal MMP-9 and TIMP-1 concentrations were determined with the sandwich enzyme-linked immunoassay technique. The performance of each marker with reference to the Paris classification, disease activity scores and magnetic resonance enterography results was assessed using non-parametric tests. A total of 32 children with CD demonstrated higher levels of serum and faecal MMP-9 and TIMP-1 compared with a control group including children without gastrointestinal inflammatory disease (all P < 0.05). Only the serum MMP-9 concentration was significantly higher in children with L3 (ileocolonic) compared with children with L1 (distal ileum). The serum TIMP-1 level was significantly higher in patients with an magnetic resonance enterography-detected ileum involvement longer than 51 mm and in children with severe disease activity compared with other patients. The serum MMP-9 level was lower in patients with stenosis combined with prestenotic dilation compared with children without stenosis. Increased serum and faecal MMP-9 and TIMP-1 concentrations are some reliable markers of inflammation in newly diagnosed children with CD, but without facilitating clear phenotyping of the disease.
Substances chimiques
Biomarkers
0
TIMP1 protein, human
0
Tissue Inhibitor of Metalloproteinase-1
0
Metalloproteases
EC 3.4.-
MMP9 protein, human
EC 3.4.24.35
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233-1241Subventions
Organisme : Uniwersytet Medyczny w Bialymstoku
ID : 153-43773L
Organisme : Uniwersytet Medyczny w Bialymstoku
ID : SUB/1/DN/19/005/1143
Informations de copyright
© 2020 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
Références
Di Narzo AF, Brodmerkel C, Telesco SE et al. High-throughput identification of the plasma proteomic signature of inflammatory bowel disease. J. Crohns Colitis 2019; 13: 462-71.
Duvoisin G, Lopez RN, Day AS, Lemberg DA, Gearry RB, Leach ST. Novel biomarkers and the future potential of biomarkers in inflammatory bowel disease. Mediators Inflamm. 2017; 2017: 1936315.
Daniluk U, Daniluk J, Kucharski R et al. Untargeted metabolomics and inflammatory markers profiling in children with Crohn's disease and ulcerative colitis - a preliminary study. Inflamm. Bowel Dis. 2019; 25: 1120-8.
Mosli MH, Zou G, Garg SK et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am. J. Gastroenterol. 2015; 110: 802-19.
Daniluk U, Daniluk J, Krasnodebska M, Lotowska JM, Sobaniec-Lotowska ME, Lebensztejn DM. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn's disease. Adv. Med. Sci. 2019; 64: 9-14.
Kolho KL, Sipponen T, Valtonen E, Savilahti E. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int. J. Colorectal Dis. 2014; 29: 43-50.
Lakatos G, Hritz I, Varga MZ et al. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig. Dis. 2012; 30: 289-95.
Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpacka M, Iwanczak B. Correlation of MMP-3 and MMP-9 with Crohn's disease activity in children. Dig. Dis. Sci. 2012; 57: 706-12.
Manfredi MA, Zurakowski D, Rufo PA, Walker TR, Fox VL, Moses MA. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2008; 14: 1091-6.
Kapsoritakis AN, Kapsoritaki AI, Davidi IP et al. Imbalance of tissue inhibitors of metalloproteinases (TIMP)-1 and -4 serum levels, in patients with inflammatory bowel disease. BMC Gastroenterol. 2008; 8: 55.
Mäkitalo L, Rintamäki H, Tervahartiala T, Sorsa T, Kolho KL. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease. Scand. J. Gastroenterol. 2012; 47: 785-94.
Schreiber S, Siegel CA, Friedenberg KA et al. A phase 2, randomized, placebo-controlled study evaluating matrix metalloproteinase-9 inhibitor, andecaliximab, in patients with moderately to severely active Crohn's disease. J. Crohns Colitis 2018; 12: 1014-20.
Stidham RW, Guentner AS, Ruma JL, Govani SM, Waljee AK, Higgins PD. Intestinal dilation and platelet:albumin ratio are predictors of surgery in stricturing small bowel Crohn's disease. Clin. Gastroenterol. Hepatol. 2016; 14: 1112-9.
Levine A, Koletzko S, Turner D et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 2014; 58: 795-806.
Levine A, Griffiths A, Markowitz J et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm. Bowel Dis. 2011; 17: 1314-21.
Turner D, Griffiths AM, Walters TD et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: Recommended cutoff values and clinimetric properties. Am. J. Gastroenterol. 2010; 105: 2085-92.
Daperno M, D'Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD. Gastrointest. Endosc. 2004; 60: 505-12.
Siloşi I, Boldeanu MV, Mogoantă S et al. Matrix metalloproteinases (MMP-3 and MMP-9) implication in the pathogenesis of inflammatory bowel disease (IBD). Rom. J. Morphol. Embryol. 2014; 55: 1317-24.
Farkas K, Saródi Z, Bálint A et al. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. J. Crohns Colitis 2015; 9: 231-7.
Jakubowska K, Pryczynicz A, Iwanowicz P et al. Expressions of matrix metalloproteinases (MMP-2, MMP-7, and MMP-9) and their inhibitors (TIMP-1, TIMP-2) in inflammatory bowel diseases. Gastroenterol. Res. Pract. 2016; 2016: 2456179.
Goffin L, Fagagnini S, Vicari A et al. Anti-MMP-9 antibody: A promising therapeutic strategy for treatment of inflammatory bowel disease complications with fibrosis. Inflamm. Bowel Dis. 2016; 22: 2041-57.
Kirkegaard T, Hansen A, Bruun E, Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004; 53: 701-9.
Meijer MJ, Mieremet-Ooms MA, van der Zon AM et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig. Liver Dis. 2007; 39: 733-9.
Karl J, Wild N, Tacke M et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin. Gastroenterol. Hepatol. 2008; 6: 1122-8.